Examine the scalp (redness, scaliness, folliculitis).
Do the hair pull test: grasp a few dozen hairs and pull lightly. Normally less than 5 hairs should come out.
Laboratory tests are used, as necessary, to exclude most common diseases that cause hair loss: anaemia (basic blood count with platelet count), hypothyroidism (TSH).
Other examinations are performed, as necessary, in a targeted manner according to justified clinical suspicion. Hair loss may be caused, for example, by iron deficiency (ferritin), kidney disease (creatinine), liver disease (ALT), zinc deficiency in conditions involving malabsorption (zinc level) or secondary syphilis (Treponema pallidum antibodies).
Male-pattern baldness (androgenetic alopecia)
Often hereditary
Diagnosis is based on clinical presentation
Hair thinning is typically most extensive at the vertex and on the temples with a receding frontal hairline.
The effect only lasts for as long as they are used, and treatment response does not become evident until after several (6-12) months.Before commencing the treatment with minoxidil or finasteride the patient should be informed about the possible adverse effects and the cost of the treatment and that it is a long-term treatment, and that discontinuation of the treatment results in the loss of any results achieved. Rare adverse effects of finasteride include, among others, erectile dysfunction, decreased libido, gynaecomastia and depression.
Female-pattern baldness (androgenetic alopecia)
Pathogenesis corresponds with the male-pattern baldness and is due to hereditary factors.
Starts mostly at a later age than in men (40-60 years).
Hair thinning is relatively even without causing the hairline recession or the bald vertex as seen in men.
The optimal dose of spironolactone is 75-100 mg/day, once daily or divided into two doses. Plasma sodium, potassium and creatinine levels should be checked 1 month after treatment onset, and thereafter as necessary.
If a woman in fertile age has intermenstrual bleeding during spironolactone treatment, spironolactone should be taken only during the 3 first weeks of the menstrual cycle. Continuous use causes intermenstrual bleeding to about one fifth of patients. Women using hormonal IUD and those beyond menopause can use spironolactone every day.
Other treatments
Hair transplantation and other plastic surgery therapies have been used for both female- and male-pattern boldness.
There is no strong evidence on the efficacy of laser treatments (low level laser therapy, LLLT) or PRP injections (platelet rich plasma).
There is no evidence on the efficacy of vitamins, trace elements, hair care products and scalp massage.
For example, stopping or starting oral contraceptives, use of antiepileptics, heparin, antithyroid medication, anabolic steroids (picture 1), some antirheumatic agents, especially chloroquine, methotrexate
Also glucocorticoid injections have been used (scarce evidence).
For example, triamcinolone acetonide is diluted to up to 2.5-10 mg/ml. Injections are performed very superficially, intradermally, in doses of 0.05-0.1 ml, at maximum 20 mg during a treatment session. If needed, the treatment is repeated at 4-12-week intervals. Bear in mind the possibility of pit-forming atrophy of the skin.
An important differential diagnosis in patchy hair loss.
There is erythema, scaling and sometimes pustule formation on the scalp.
More common in children.
Diagnosis is based on positive result in fungal samples.
Treatment consists of systemic antifungal drugs.
Traction alopecia
Caused by physical or chemical factors that damage hair (excessive combing, too tight ponytail, dread hairstyle, local use of heat, e.g. for straightening hair, hair dyeing, etc.).
Causes patchy incomplete alopecia, usually in the frontal and temporal hairline.
Treatment is based on avoiding any traction and irritation of hair shafts.
Trichotillomania
A rare obsessive-compulsive disorder that involves pulling ones hair from limited scalp areas.
Usually causes incomplete patchy alopecia near the frontal or temporal hairline. There are, however, healthy hairs growing through the scalp stubble in the middle of the patches. The scalp skin is usually normal.
Most common in children and adolescents, but can be encountered in any age group.
Kanti V, Messenger A, Dobos G ym. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version. J Eur Acad Dermatol Venereol 2018;32(1):11-22. [PubMed]
Schmidt TH, Shinkai K. Evidence-based approach to cutaneous hyperandrogenism in women. J Am Acad Dermatol 2015;73(4):672-90. [PubMed]
Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol 2014;15(3):217-30. [PubMed]
van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane systematic review. Br J Dermatol 2012;167(5):995-1010. [PubMed]
Phillips TG, Slomiany WP, Allison R. Hair Loss: Common Causes and Treatment. Am Fam Physician 2017;96(6):371-378. [PubMed]
Burns LJ, De Souza B, Flynn E ym. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol 2020;83(1):276-278. [PubMed]